Cytoplasmic Granules

Example 4

Composition H was manufactured according to the following procedure:

• a) Specified amount of purified water was taken in a suitable container and specified quantity of docusate sodium was added and stirred continuously to obtain a solution.
• b) Sodium lauryl sulphate was added to the step (a) solution and stirred continuously to obtain a solution.
• c) Hydroxypropyl methyl cellulose was added to the step (b) solution and stirred continuously to obtain a solution.
• d) Mifepristone was added to the step (c) solution and stirred for 5 minutes to obtain Mifepristone dispersion.
• e) Mifepristone dispersion was homogenized using IKA's Ultra TURRAX® homogenizer at 1000 RPM for 15 minutes.
• f) The above homogenized mifepristone slurry was nano-sized in ball-mill chamber to obtain nano-suspension containing desired particle size of mifepristone. The particle size distribution was measured by using Mastersizer 3000 particle analyser.
• g) Specified quantities of the silicified microcrystalline cellulose and sodium starch glycolate were dispensed in a bowl and warmed to reach 28° C. to 30° C. temperature.
• h) The nano-sized mifepristone suspension according to step (f) was sprayed onto the warmed intra-granular material according to step (g). The sprayed granules were dried at a temperature of 50° C. to 65° C. and sieved through 30 number mesh sieve.
• i) Specified quantities of milled granules of step (h), sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate were blended and compressed using tablet compression machine. The tablets according to step (i) were coated with suitable coating materials.

Example 2

100 mg of the Sarcodon aspratus extracts according to the present invention;

an appropriate amount of a vitamin mixture;

70 μg of vitamin A acetate;

1.0 mg of vitamin E;

0.13 mg of vitamin B1;

0.15 mg of vitamin B2;

0.5 mg of vitamin B6;

0.2 μg of vitamin B12;

10 mg of vitamin C;

10 μg of biotin;

1.7 mg of nicotinic acid amide;

50 μg of folate;

0.5 mg of calcium pantothenate;

an appropriate amount of a mineral mixture;

1.75 mg of ferrous sulfide;

0.82 mg of zinc oxide;

25.3 mg of magnesium carbonate;

15 mg of potassium phosphate monobasic;

55 mg of dicalcium phosphate;

90 mg of potassium citrate;

100 mg of calcium carbonate; and

24.8 mg of magnesium chloride.

The composition ratio of the vitamins and the mineral mixture described above may be determined according to a composition ratio used in general functional health foods, and the combination ratio of the vitamins and the mineral mixture may be arbitrarily determined. According to a conventional method of preparing functional health foods, these components are mixed, granules are prepared, and the granules are used to prepare a composition for a functional health food.

Example 3

Bifidobacterium breve M-16V (NITE BP-02622) is added to 3 mL of an MRS liquid medium and is anaerobically cultured at 37° C. for 16 hours, and the culture liquid is concentrated, followed by lyophilization, to obtain a lyophilized powder of the bacterium (bacterial powder). Next, crystalline cellulose is put in an agitation granulator and mixed. Then, purified water was added, followed by granulation. The granulated product is dried to obtain granules that contain an extracted component of the bacterium and an excipient. By administering the composition, modulation of palatability, maintenance of body temperature, and protection of a blood vessel can be expected. Furthermore, the composition can be used for preventing or treating unbalanced diet, sensitivity to cold, hypothermia, myocardial infarction, ischemia-reperfusion injury, cardiac hypertrophy, diabetic cardiomyopathy, arteriosclerosis, or vascular plaque formation.